Skip to main content
Premium Trial:

Request an Annual Quote

Strand Genomics, HCG Collaborate on Cancer in India

NEW YORK (GenomeWeb) – Strand Genomics today announced an initiative with Health Care Global Enterprises to provide personalized cancer genomics services in India.

As part of the deal, Strand — through The Strand-Triesta Center for Cancer Genomics — will provide to HCG its clinical genomics products and services, including saliva-based testing to evaluate a patient's risk of developing cancer, as well as molecular diagnosis, treatment options, and clinical trial recommendations based on tumor DNA. The Strand-Triesta Center is a partnership between Strand and Triesta Sciences, a unit of HCG.

According to Strand, the initiative leverages its end-to-end clinical solutions comprising tests and interpretation services based on next-generation sequencing and its StrandOmics data analysis and interpretation service platform to profile tumors in search of actionable mutations.

Based in Bangalore, India, Strand provides genomics testing. It has US offices in San Francisco and Rockville, Md. HCG is a dedicated cancer care network with 27 centers in India servicing more than 100,000 new patients each year.